Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | PARP1 | P09874 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080590 | 0.89 | OPRM1 (0.48) | DRD4DRD3DRD2PARP1OPRM1 | |
| SCHEMBL8426990 | 0.78 | KDM4E (0.51) | DRD4DRD3DRD2OPRM1OPRK1 | |
| SCHEMBL8426987 | 0.78 | KDM4E (0.51) | DRD4DRD3DRD2OPRM1OPRK1 | |
| SCHEMBL5754611 | 0.76 | MAPT (0.57) | DRD4DRD3DRD2F7LTA4H | |
| SCHEMBL10287534 | 0.76 | SIGMAR1 (0.71) | DRD4DRD3DRD2OPRM1OPRK1 | |
| SCHEMBL8705132 | 0.74 | DRD4 (0.83) | DRD4DRD3DRD2PARP1OPRM1 | |
| SCHEMBL5752080 | 0.74 | MEN1 (0.58) | DRD4DRD3DRD2PARP1OPRM1 | |
| SCHEMBL10371700 | 0.72 | SIGMAR1 (0.54) | DRD4DRD3DRD2PARP1MAPK1 | |
| SCHEMBL8300847 | 0.72 | PARP1 (0.39) | DRD4DRD3DRD2PARP1OPRM1 | |
| SCHEMBL8426843 | 0.72 | KDM4E (0.49) | DRD4DRD3DRD2ABCB1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | claimed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | claimed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | claimed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | disclosed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | disclosed |
| US-6958338-B2 | 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-10-25 | — | — | US | disclosed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| EP-1309586-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016349-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, SLC6A3, HTR6 | DRD4 4/4885DRD3 5/4885DRD2 6/4885 |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, HTR6, SLC6A3 | DRD4 10/4885DRD3 9/4885DRD2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.